利妥昔单抗治疗难治性抗合成酶综合征。 - Suppr

Suppr

超能文献

Refractory anti-synthetase syndrome treated with rituximab.

作者信息

Ball Elisabeth M A, Savage Eimear M, Pendleton Adrian

出版信息

Rheumatology (Oxford). 2010 May;49(5):1013. doi: 10.1093/rheumatology/kep438. Epub 2009 Dec 23.

DOI:10.1093/rheumatology/kep438

PMID:20032227

Abstract

摘要

相似文献

Refractory anti-synthetase syndrome treated with rituximab.

Rheumatology (Oxford). 2010 May;49(5):1013. doi: 10.1093/rheumatology/kep438. Epub 2009 Dec 23.

Rituximab treatment of the anti-synthetase syndrome: a retrospective case series.

Rheumatology (Oxford). 2009 Aug;48(8):968-71. doi: 10.1093/rheumatology/kep157. Epub 2009 Jun 16.

[Beneficial effects of rituximab in the treatment of refractory nephrotic syndrome].

Nihon Jinzo Gakkai Shi. 2012;54(5):593-7.

Rituximab-induced pulmonary disease.

Rheumatol Int. 2012 Sep;32(9):2955-6. doi: 10.1007/s00296-011-2110-9. Epub 2011 Sep 3.

Rituximab and lupus interstitial lung disease: friend or foe?

Int J Rheum Dis. 2011 Feb;14(1):e3-4. doi: 10.1111/j.1756-185X.2010.01592.x. Epub 2011 Jan 24.

Rituximab-induced interstitial lung disease: case report and literature review.

Pharmacology. 2011;87(5-6):318-20. doi: 10.1159/000327681. Epub 2011 May 26.

Comment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.

Rheumatology (Oxford). 2010 Sep;49(9):1795-6; author reply 1796-7. doi: 10.1093/rheumatology/keq141. Epub 2010 May 19.

Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome.

Respir Med. 2012 Apr;106(4):581-7. doi: 10.1016/j.rmed.2012.01.001. Epub 2012 Jan 24.

Successful use of rituximab in recalcitrant skin predominant dermatomyositis.

J Clin Rheumatol. 2011 Mar;17(2):111-2. doi: 10.1097/RHU.0b013e31821072b7.

Stiff-person syndrome: persistent elevation of glutamic acid decarboxylase antibodies despite successful treatment with rituximab.

J Clin Rheumatol. 2010 Aug;16(5):237-9. doi: 10.1097/RHU.0b013e3181e931fa.

引用本文的文献

Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review.

J Clin Med. 2020 Feb 3;9(2):407. doi: 10.3390/jcm9020407.

Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies.

Clin Med Insights Circ Respir Pulm Med. 2015 Jul 23;9(Suppl 1):9-17. doi: 10.4137/CCRPM.S23313. eCollection 2015.

Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Curr Rheumatol Rep. 2012 Jun;14(3):264-74. doi: 10.1007/s11926-012-0246-6.

J Bras Pneumol. 2011 Jan-Feb;37(1):100-9. doi: 10.1590/s1806-37132011000100015.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Refractory anti-synthetase syndrome treated with rituximab.

作者信息

Ball Elisabeth M A, Savage Eimear M, Pendleton Adrian

出版信息

Rheumatology (Oxford). 2010 May;49(5):1013. doi: 10.1093/rheumatology/kep438. Epub 2009 Dec 23.

DOI:10.1093/rheumatology/kep438

PMID:20032227

Abstract

摘要

相似文献

Refractory anti-synthetase syndrome treated with rituximab.

Rheumatology (Oxford). 2010 May;49(5):1013. doi: 10.1093/rheumatology/kep438. Epub 2009 Dec 23.

Rituximab treatment of the anti-synthetase syndrome: a retrospective case series.

Rheumatology (Oxford). 2009 Aug;48(8):968-71. doi: 10.1093/rheumatology/kep157. Epub 2009 Jun 16.

[Beneficial effects of rituximab in the treatment of refractory nephrotic syndrome].

Nihon Jinzo Gakkai Shi. 2012;54(5):593-7.

Rituximab-induced pulmonary disease.

Rheumatol Int. 2012 Sep;32(9):2955-6. doi: 10.1007/s00296-011-2110-9. Epub 2011 Sep 3.

Rituximab and lupus interstitial lung disease: friend or foe?

Int J Rheum Dis. 2011 Feb;14(1):e3-4. doi: 10.1111/j.1756-185X.2010.01592.x. Epub 2011 Jan 24.

Rituximab-induced interstitial lung disease: case report and literature review.

Pharmacology. 2011;87(5-6):318-20. doi: 10.1159/000327681. Epub 2011 May 26.

Rheumatology (Oxford). 2010 Sep;49(9):1795-6; author reply 1796-7. doi: 10.1093/rheumatology/keq141. Epub 2010 May 19.

Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome.

Respir Med. 2012 Apr;106(4):581-7. doi: 10.1016/j.rmed.2012.01.001. Epub 2012 Jan 24.

Successful use of rituximab in recalcitrant skin predominant dermatomyositis.

J Clin Rheumatol. 2011 Mar;17(2):111-2. doi: 10.1097/RHU.0b013e31821072b7.

Stiff-person syndrome: persistent elevation of glutamic acid decarboxylase antibodies despite successful treatment with rituximab.

J Clin Rheumatol. 2010 Aug;16(5):237-9. doi: 10.1097/RHU.0b013e3181e931fa.

引用本文的文献

Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review.

J Clin Med. 2020 Feb 3;9(2):407. doi: 10.3390/jcm9020407.

Recent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory Myopathies.

Clin Med Insights Circ Respir Pulm Med. 2015 Jul 23;9(Suppl 1):9-17. doi: 10.4137/CCRPM.S23313. eCollection 2015.

Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.

Curr Rheumatol Rep. 2012 Jun;14(3):264-74. doi: 10.1007/s11926-012-0246-6.

J Bras Pneumol. 2011 Jan-Feb;37(1):100-9. doi: 10.1590/s1806-37132011000100015.